Medivir: Strategic Pipeline Prioritisation at IGM Biosciences - Redeye
Bildkälla: Stockfoto

Medivir: Strategic Pipeline Prioritisation at IGM Biosciences - Redeye

Redeye comments on the cost reduction program at IGM Biosciences which impacts birinapant, which is licensed from Medivir.

Börsvärldens nyhetsbrev